สำนักราชบัณฑิตยสภา

The Journal of the Royal Institute of Thailand Volume II - 2010 Combination Anti-malarial Therapy and WHO Recommendations 106 has the advantages of simplicity, and where available, a fixed-dose combination formulation improves compliance. Antimalarial treatments on the basis of the evidence from current practice and the consensus opinion regarding preference may use an alternative ACT known to be effective in the region e.g. artesunate plus tetracycline or doxycycline or clindamycin, quinine plus tetracycline or doxycycline or clindamycin . References Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ, 2009. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med , 361: 455-467. Pukrittayakamee S, Chantra A, Vanijanonta S, Clemens R, Looareesuwan S, White NJ, 2000. Therapeutic responses to quinine and clindamycin in multidrug resistant falciparum malaria. Antimicrob Agents Chemother , 44: 2395-2398. Pukrittayakamee S, White NJ, 2002. Combination therapy: making the best use of existing drugs. Pharmaceutical News , 8: 21-25. WHO. Guidelines for the treatment of malaria, second edition. WHO , 2010